Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.
2.

Bio-activity of natural polymers from the genus Pistacia: a validated model for their antimicrobial action.

Sharifi MS, Ebrahimi D, Hibbert DB, Hook J, Hazell SL.

Glob J Health Sci. 2011 Dec 29;4(1):149-61. doi: 10.5539/gjhs.v4n1p149.

3.

Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model.

Kotiw M, Johnson M, Pandey M, Fry S, Hazell SL, Netter HJ, Good MF, Olive C.

Clin Vaccine Immunol. 2012 Feb;19(2):268-76. doi: 10.1128/CVI.05295-11. Epub 2011 Dec 28.

4.

Evasion of the Toxic Effects of Oxygen.

Hazell SL, Harris AG, Trend MA.

In: Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacter pylori: Physiology and Genetics. Washington (DC): ASM Press; 2001. Chapter 15.

5.

Overview.

Mobley HLT, Mendz GL, Hazell SL.

In: Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacter pylori: Physiology and Genetics. Washington (DC): ASM Press; 2001. Chapter 1.

6.

Fractionation of Mastic Gum in Relation to Antimicrobial Activity.

Sharif Sharifi M, Hazell SL.

Pharmaceuticals (Basel). 2009 Apr 1;2(1):2-10.

7.

Detection of HSV type-1 and type-2 IgG using an in vitro PCA based homogeneous immunoassay.

Fry SR, Li J, de las Heras R, McCourt JA, Arel E, Kachab EH, Hazell SL, Huang CY.

Biochem Biophys Res Commun. 2008 Aug 8;372(4):542-6. doi: 10.1016/j.bbrc.2008.05.075. Epub 2008 May 27.

PMID:
18503749
8.

Development of homogeneous immunoassays based on protein fragment complementation.

de las Heras R, Fry SR, Li J, Arel E, Kachab EH, Hazell SL, Huang CY.

Biochem Biophys Res Commun. 2008 May 23;370(1):164-8. doi: 10.1016/j.bbrc.2008.03.057. Epub 2008 Mar 19.

PMID:
18358235
9.

Clinical utility of avidity assays.

Hazell SL.

Expert Opin Med Diagn. 2007 Dec;1(4):511-9. doi: 10.1517/17530059.1.4.511.

PMID:
23496357
10.

Immunoglobulin G avidity in differentiation between early and late antibody responses to West Nile virus.

Fox JL, Hazell SL, Tobler LH, Busch MP.

Clin Vaccine Immunol. 2006 Jan;13(1):33-6.

11.

Serological diagnosis of West Nile virus.

Hazell SL.

MLO Med Lab Obs. 2004 Jun;36(6):10-2, 16; quiz 18-9. No abstract available.

PMID:
15242177
13.

Strategies for the enrichment and identification of basic proteins in proteome projects.

Bae SH, Harris AG, Hains PG, Chen H, Garfin DE, Hazell SL, Paik YK, Walsh BJ, Cordwell SJ.

Proteomics. 2003 May;3(5):569-79.

PMID:
12748937
14.

Catalase (KatA) and KatA-associated protein (KapA) are essential to persistent colonization in the Helicobacter pylori SS1 mouse model.

Harris AG, Wilson JE, Danon SJ, Dixon MF, Donegan K, Hazell SL.

Microbiology. 2003 Mar;149(Pt 3):665-72.

PMID:
12634335
15.
16.

Potential involvement of several nitroreductases in metronidazole resistance in Helicobacter pylori.

Jorgensen MA, Trend MA, Hazell SL, Mendz GL.

Arch Biochem Biophys. 2001 Aug 15;392(2):180-91.

PMID:
11488591
17.

Association between the IgG subclass response, inflammation and disease status in Helicobacter pylori infection.

Mitchell HM, Mascord K, Hazell SL, Daskalopoulos G.

Scand J Gastroenterol. 2001 Feb;36(2):149-55.

PMID:
11252406
18.

Oxidases and reductases are involved in metronidazole sensitivity in Helicobacter pylori.

Trend MA, Jorgensen MA, Hazell SL, Mendz GL.

Int J Biochem Cell Biol. 2001 Feb;33(2):143-53.

PMID:
11240371
19.

The Helicobacter pylori pyrB gene encoding aspartate carbamoyltransferase is essential for bacterial survival.

Burns BP, Hazell SL, Mendz GL, Kolesnikow T, Tillet D, Neilan BA.

Arch Biochem Biophys. 2000 Aug 1;380(1):78-84.

PMID:
10900135
20.

Use of digoxigenin-labelled ampicillin in the identification of penicillin-binding proteins in Helicobacter pylori.

Harris AG, Hazell SL, Netting AG.

J Antimicrob Chemother. 2000 May;45(5):591-8.

PMID:
10797079
21.

Fumarate metabolism and the microaerophily of Campylobacter species.

Smith MA, Mendz GL, Jorgensen MA, Hazell SL.

Int J Biochem Cell Biol. 1999 Sep;31(9):961-75.

PMID:
10533287
22.

Metabolism and genetics of Helicobacter pylori: the genome era.

Marais A, Mendz GL, Hazell SL, M├ęgraud F.

Microbiol Mol Biol Rev. 1999 Sep;63(3):642-74. Review.

23.

Will Helicobacter pylori be the next organism for which we will have exhausted our treatment options?

Hazell SL.

Eur J Clin Microbiol Infect Dis. 1999 Feb;18(2):83-6. No abstract available.

PMID:
10219573
24.

The tricarboxylic acid cycle of Helicobacter pylori.

Pitson SM, Mendz GL, Srinivasan S, Hazell SL.

Eur J Biochem. 1999 Feb;260(1):258-67.

25.

The prevalence of antibody to CagA in children is not a marker for specific disease.

Mitchell HM, Hazell SL, Bohane TD, Hu P, Chen M, Li YY.

J Pediatr Gastroenterol Nutr. 1999 Jan;28(1):71-5.

PMID:
9890472
26.
27.

Metronidazole resistance and microaerophily in Campylobacter species.

Smith MA, Jorgensen MA, Mendz GL, Hazell SL.

Arch Microbiol. 1998 Oct;170(4):279-84.

PMID:
9732442
28.

Characterization of fumarate transport in Helicobacter pylori.

Mendz GL, Meek DJ, Hazell SL.

J Membr Biol. 1998 Sep 1;165(1):65-76.

PMID:
9705983
29.
30.

The mode of action of metronidazole in Helicobacter pylori: futile cycling or reduction?

Jorgensen MA, Manos J, Mendz GL, Hazell SL.

J Antimicrob Chemother. 1998 Jan;41(1):67-75.

PMID:
9511039
31.

Purine metabolism and the microaerophily of Helicobacter pylori.

Mendz GL, Shepley AJ, Hazell SL, Smith MA.

Arch Microbiol. 1997 Dec;168(6):448-56.

PMID:
9385135
32.

A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation (China).

Mitchell HM, Hu P, Chi Y, Chen MH, Li YY, Hazell SL.

Gastroenterology. 1998 Feb;114(2):256-61.

PMID:
9453484
33.

Catalase, a novel antigen for Helicobacter pylori vaccination.

Radcliff FJ, Hazell SL, Kolesnikow T, Doidge C, Lee A.

Infect Immun. 1997 Nov;65(11):4668-74.

34.

In situ properties of Helicobacter pylori aspartate carbamoyltransferase.

Burns BP, Mendz GL, Hazell SL.

Arch Biochem Biophys. 1997 Nov 1;347(1):119-25.

PMID:
9344472
35.

Influence of a proton pump inhibitor-based therapy on Helicobacter pylori strain selection.

Hazell SL, Mitchell HM, Hanna G, Daskalopoulos G.

Eur J Clin Microbiol Infect Dis. 1997 Jul;16(7):530-2.

PMID:
9272389
36.

Genetic relationship among isolates of Helicobacter pylori: evidence for the existence of a Helicobacter pylori species-complex.

Hazell SL, Andrews RH, Mitchell HM, Daskalopoulous G.

FEMS Microbiol Lett. 1997 May 1;150(1):27-32.

37.

How Helicobacter pylori works: an overview of the metabolism of Helicobacter pylori.

Hazell SL, Mendz GL.

Helicobacter. 1997 Mar;2(1):1-12. Review. No abstract available.

PMID:
9432315
38.

Lansoprazole and amoxycillin: observations on the treatment of Helicobacter pylori infection.

Hazell SL, Daskalopoulous G, Mitchell HM, Massey D.

J Gastroenterol Hepatol. 1997 Feb;12(2):93-9.

PMID:
9083908
39.

Helicobacter pylori, gastric ulcer, and duodenal ulcer.

Mitchell HM, Hazell SL.

N Engl J Med. 1996 Dec 12;335(24):1841; author reply 1842-3. No abstract available.

PMID:
8965891
40.

The urea cycle of Helicobacter pylori.

Mendz GL, Hazell SL.

Microbiology. 1996 Oct;142 ( Pt 10):2959-67.

PMID:
8885413
41.
42.
43.

Antigen recognition during progression from acute to chronic infection with a cagA-positive strain of Helicobacter pylori.

Mitchell HM, Hazell SL, Kolesnikow T, Mitchell J, Frommer D.

Infect Immun. 1996 Apr;64(4):1166-72.

44.

Isolation of "Helicobacter heilmannii" from human tissue.

Hazell SL.

Eur J Clin Microbiol Infect Dis. 1996 Jan;15(1):4-9. No abstract available.

PMID:
8641302
45.

Acetyl-CoA carboxylase activity in Helicobacter pylori and the requirement of increased CO2 for growth.

Burns BP, Hazell SL, Mendz GL.

Microbiology. 1995 Dec;141 ( Pt 12):3113-8.

PMID:
8574404
46.

Aminoacid utilization by Helicobacter pylori.

Mendz GL, Hazell SL.

Int J Biochem Cell Biol. 1995 Oct;27(10):1085-93.

PMID:
7496998
47.

Fumarate reductase: a target for therapeutic intervention against Helicobacter pylori.

Mendz GL, Hazell SL, Srinivasan S.

Arch Biochem Biophys. 1995 Aug 1;321(1):153-9.

PMID:
7639515
48.

Gastric atrophy and regional variation in upper gastrointestinal disease.

Hu PJ, Li YY, Lin HL, Zhou SM, Du G, Chen MH, Mitchell HM, Hazell SL.

Am J Gastroenterol. 1995 Jul;90(7):1102-6.

PMID:
7611205
49.

Characterisation of glucose transport in Helicobacter pylori.

Mendz GL, Burns BP, Hazell SL.

Biochim Biophys Acta. 1995 Jun 9;1244(2-3):269-76.

PMID:
7599143
50.

Supplemental Content

Loading ...
Support Center